[7] One report[clarification needed] attributes Stryker's rise from a maker of hospital beds to a world-class medical technology company to Brown.

In February of the same year, the firm acquired eTrauma.com, a privately held entity involved in the development of software for Picture archiving and communication system (PACS); the company was incorporated into Stryker Endoscopy Business.

In January 2011, Stryker acquired the Neurovascular Division of Boston Scientific, which includes products used for the minimally invasive treatment of hemorrhagic and ischemic stroke.

[15] In November 2012, Stryker acquired the Tel Aviv, Israel-based Surpass Medical Ltd., a company developing a flow diversion stent technology to treat brain aneurysms using a mesh design and delivery system, for $135 million.

[25] In June 2017, Stryker acquired Arthrogenx, LLC, which developed the Cobra reusable suture passer for arthroscopic rotator cuff repair [26] and Novadaq.

[41][42] In 2023, Stryker has introduced a new minimally invasive bunion treatment system, Prostep MIS Lapidus, as part of its growing extremities portfolio, acquired through its takeover of Wright Medical in 2020.

The device aims to reduce bunion recurrence, minimize scarring, and lower opioid use, debuting at the 2023 American Orthopaedic Foot & Ankle Society Annual Meeting.

[47][48] The first of these, a seven-page correspondence, named various issues at an Irish manufacturing facility, such as untimely fix of failures and procedural noncompliance in the testing of failed or otherwise problem-prone devices.

[49] The second, sent November 2007, cites issues at the firm's Mahwah, New Jersey, facility, including poor fixation of hip implant components, in some instances requiring mitigation by revision surgeries; exceeded microbial level violations in the cleaning and final packaging areas of the sterile implants; and failure to institute measures in prevention of recurrence of these and other problems.

Again, issues relate to quality and noncompliance including falsification of documents relevant to the selling of products to hospitals which are to be sold under a limited, government-mandated basis.

[51] In the fall of 2007, Stryker, along with the related companies Biomet, Zimmer Holdings, DePuy Orthopaedics and Smith & Nephew, were involved in civil litigation with the U.S. Department of Health and Human Services, Office of Inspector General.

This litigation called for a net payout of $311 million as the governmental department maintains the aforementioned companies engaged in unlawful kickbacks to physicians who urged hospitals to purchase their respective products.

[53] Stryker recalled several models of medical vacuums sold under the Neptune Waste Management System brand in June and September 2012.

The devices, some of which had not been cleared by the Food and Drug Administration, caused a fatal accident when the vacuum was mistakenly used to suction a passive drainage tube.

[56] In 2016, subsidiary company Stryker EMEA Supply Chain Services BV challenged the Dutch authorities' interpretation of procurement nomenclature regarding implant screws intended to be inserted in the human body.

The matter was referred to the European Court of Justice for a preliminary ruling on the legal position and on the validity of the relevant EU implementing regulation.

[57] During the 2022 Russian invasion of Ukraine, Stryker was among those that continued business-as-usual in Russia rather than join the more than a thousand international corporations that have curtailed operations there.

Research from Yale School of Management evaluating companies' reaction to the Russian invasion put Stryker in the "Grade F" category of "Digging In", meaning "Defying Demands for Exit or Reduction of Activities.